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Tandem duplicationHuman D-type prostanoid (DP) and E-type prostanoid 2 (EP2) receptors are regarded as the most
closely related receptors among prostanoid receptors. Although these receptors are generated by
tandem duplication, their physiological outputs often oppose one another. In the present study,
we extracted mutations occurring in the coding regions of both receptors using the 1000 genome
project database and found that EP2 receptors have 8-fold fewer amino acid mutations. We
speculate that EP2 receptors exhibit more constraints to mutations than DP receptors.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Prostanoids are lipid mediators and play very important roles in
the generation of inﬂammatory responses. Although, inﬂammation
is essentially beneﬁcial for infections and injuries, it has occasion-
ally been implicated in the pathogeneses of cancer, arthritis, stroke,
and/or cardiovascular as well as neurodegenerative diseases [1].
Prostaglandin E2 (PGE2) is the most abundant of the ﬁve main pros-
tanoids, throughout the body and acts as a very potent mediator
that exhibits many biological activities [1,2]. The most important
features of PGE2 are the roles it plays in vasodilation, embryo
implantation, contraction as well as relaxation of smooth muscle
cells, gastrointestinal motility, neuroprotective functions, and
inﬂammation [2,3]. Prostaglandin D2 (PGD2), a positional isomer
of PGE2, has been characterized as a regulator of sleep, and isinvolved in the initiation of type-I acute allergic responses includ-
ing asthma in peripheral [1].
Although the diverse actions of prostanoids, including PGD2 and
PGE2, have been characterized, these functions are inefﬁcient if
their cognate receptors, i.e. the prostanoid receptors, are absent.
The eight types and subtypes of prostanoid receptors are the family
of G-protein coupled receptors and are known as DP for PGD2, EP1
to EP4 for PGE2, FP for prostaglandin F2a (PGF2a), IP for
prostaglandin I2 (PGI2) or prostacyclin, and TP for thromboxane
A2 (TXA2) [4,5]. In addition to the eight prostanoid receptors, a
distinct type of PGD2 receptor belongs to the family of chemokine
receptors, namely the chemo-attractant receptor-homologous
molecule expressed on T helper type 2 cells (CRTH2) receptor
[4,5]. Therefore, PGD2 principally elicits its functions through the
activation of DP receptors and CRTH2 receptors, whereas PGE2
largely exerts its actions via EP1 to EP4 receptors.
The structures of PGD2 and PGE2 as positional isomers are very
similar; however, these isomers sometimes exhibit opposite effects
on the body [6]; for example, PGE2 has been shown to induce
elevations in body temperature, whereas PGD2 lowers it [6]. PGE2
has also been reported to suppress food intake, whereas PGD2
increases it [6]. PGD2 and PGE2 exert opposite effects in the
regulation of asthma, as well as the regulation of wakefulness/
sleep in central.
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bronchial hyper-responsiveness, airway inﬂammation, and eleva-
tions in the levels of immunoglobulin E, which activates mast cells
to produce PGD2 [7,8]. Thus, increases in PGD2 have been detected
in asthmatic patients following an endo-bronchial allergen chal-
lenge [7,8]. Certain key regulators of asthma appear to be elicited
by PGD2 acting on DP receptors, and this has also been conﬁrmed
in studies using knockout mice [8,9]. While PGD2 is considered to
be crucially involved in the deterioration of asthma, PGE2 may have
potentially beneﬁcial effects on this disease [10]. Thus, the activity
of human and murine mast cells was found to be prevented by
PGE2 through the activation of EP2 receptors in vitro [10]. Further-
more, the activity of airway mast cells in mouse models of asthma
was inhibited by both endogenous PGE2 and/or exogenously
administered PGE2 in vivo, possibly through EP2 receptor-mediat-
ed mechanisms, which has also been supported by studies using
knockout mice [10,11].
The most abundant prostanoid in the brain is PGD2, which has
been identiﬁed as a potent humoral sleep-inducing factor [12].
Previous knockout studies demonstrated that, PGD2-activated DP
receptors were important for inducing sleep, and the mechanism
responsible was proposed as the production and release of adeno-
sine [12,13]. On the other hand, the onset and maintenance of
wakefulness is assumed to be regulated by PGE2 [14,15].
PGE2-mediated wakefulness is generally associated with the
activation of EP4 receptors [15]; however, it is also reported to
be mediated by EP1 and EP2 receptors [16].
In spite of the opposing effects of PGD2/DP receptors and PGE2/
EP2 receptors on the regulation of pathological conditions such as
asthma, human EP2 and DP receptors are Gas-coupled receptors
and the most homologically related receptors among prostanoid
receptors [4,17–19]. Both receptor genes are located at chromo-
some 14q22 in humans (approximately 52.73–52.74 Mb in the
DP receptor and 52.78–52.80 Mb in the EP2 receptor) and consist
of very similar amounts of amino acids; 359 amino acids for DP
receptors and 358 amino acids for EP2 receptors [7,20–22]. These
genes are considered to be generated by tandem duplication
[21]; therefore, both receptors are typically placed side by side in
the phylogenetic tree of prostanoid receptors [4,19].
In the present study, we focused on extracted mutations that
occurred in the coding regions of human DP and EP2 receptors
using the 1000 genome project database and found that EP2
receptors had less mutations than DP receptors, especially at the
amino acid level. These results suggest that constrained EP2
receptors may have irreplaceable functions, and/or DP receptors
may undergo more mutations than EP2 receptors, thereby gaining
new functions as a new copy of a duplicated gene.
2. Materials and methods
2.1. Identiﬁcation of single nucleotide polymorphisms (SNPs) in DP and
EP2 receptors
SNP data from the 1000 genomes project for Homo sapiens
(GRCh37.p13) were used in the present study [23–26]. VCF ﬁles
were processed by VCFtools (v0.1.11) [27] to obtain SNP informa-
tion for each 13 of the genes examined, including DP and EP2
receptors, based on their locations on the genome, as shown in
Supplementary Table I. Data for Mus muscus (GRCm.38.p2) were
extracted from theWellcome Trust Sanger Institute mouse genome
project [28] (http://www.sanger.ac.uk/resources/mouse/genomes/
), and the genome sequences of 17 key strains were processed in
the same manner. SNP information was generated based on the
locations of the genes in Supplementary Table I.2.2. R/S ratio of stochastic frequency
The number of substitutions per silent site (S) and the number
of substitutions per replacement site (R) of the prostanoid recep-
tors were extracted, followed by a calculation of the R/S ratios in
a similar manner to the stochastic rate, as reported previously [29].
3. Results
One of the most prevalent and important phenomena for dupli-
cating genes is the acquisition of new functions to adapt to and/or
deal with a new environment and/or condition [30,31]. However,
since evolutionally complete functional redundancy is considered
to be unstable in the long term, the equality of duplicated gene
copies must be disrupted, e.g. by mutations, if they are to be
preserved [32]. Therefore, to examine differences between a pair
of duplicates, DP and EP2 receptors, we extracted the numbers of
mutations occurring in the coding sequence (CDS) regions of
human DP and EP2 receptors, using the 1000 genome project
database; an integrated map from 1092 human genomes of 14
populations extracted from Europe, East Asia, sub-Saharan Africa,
and the Americans [23]. As shown in Figs. 1 and 2, a total of 20
and 12 nucleotide changes were detected in the DP and EP2
receptors, respectively. Four out of the 20 nucleotides changes in
DP receptors were silent mutations; therefore, their amino acid
residues were conserved (Fig. 1). However, 9 out of the 12
nucleotides were silent in EP2 receptors (Fig. 2). Thus, the actual
substitution of amino acids was 16 in DP receptors, but only 4 in
EP2 receptors, as shown in Figs. 1 and 2. Seventeen nucleotide
changes were detected and 11 amino acids were replaced with
other amino acids in other Gas-coupled human EP4 receptors;
and 22 nucleotides were changed and 8 amino acids were
substituted in human IP receptors (data not shown). Therefore, in
terms of amino acid replacements, among Gas-coupled prostanoid
receptors, less substitutions were detected in EP2 receptors.
According to the assumption that silent mutations are largely
unaffected by natural selection; therefore, the stochastic rate of
the accumulation of silent mutations will be proportional to time
[29]. Thus, the number of silent mutations in a pair of duplicates,
in this case DP and EP2 receptors, should be similar if selective
constraints do not exist; i.e. the evolutional stochastic rates of
silent mutations will be the same. As shown in Figs. 1 and 2, the
number of silent mutations was mapped by comparing the
reference sequences of each receptor; NM_000953.2 for DP
receptors and NM_000956.3 for EP2 receptors, respectively, and
not by comparing between DP and EP2 receptors. Therefore, the
numbers of mutations shown in Figs. 1 and 2 were extracted from
comparisons of a pair of DP receptor reference sequences (ref_DP)
and the 1000 genome project database DP receptor sequences
(dbs_DP), and the same was performed for EP2 receptors. Thus,
similar to the stochastic rate in evolution, the stochastic frequency
of silent mutations extracted from 1092 people in the genome pro-
ject in the current era should be similar between ref_DP/dbs_DP
and ref_EP2/dbs_EP2 if selective constraints do not exist.
The traditional approach was useful to deduce the magnitude of
selective constraint on protein evolution of comparing the rates of
nucleotide substitution at replacement and silent sites [29]. Thus,
the ratio of the number of substitutions per amino acid replace-
ment site (R)/number of substitutions per silent site (S) was <1
when selective constraints existed, whereas the R/S ratio was >1,
with the acceleration of protein evolution [29]. Again in this case,
it is not the stochastic rate, but the stochastic frequency of 1092
people worldwide (2184 sets of genes) in the current era, the
number of substitutions per silent site (S) and the number of
Fig. 1. Mutations in the coding sequences of human DP receptors extracted from the 1000 genome project database. The chromosome, nucleotide, and amino acid positions of
human DP receptors were referred from GRCh37.p13 of NM_000953.2 (nucleotide ID) and NP_000944.1 (protein ID). The red ﬁlled frames were missense, non-sense, or frame
shifted variants (amino acid position: contig reference amino acid/changed amino acid or non-sense ‘‘*’’). The light orange ﬁlled frames were synonymous variants (amino
acid position: silent mutation ‘‘sm’’).
768 J. Tanimoto et al. / FEBS Letters 589 (2015) 766–772substitutions per replacement site (R) were measured using the
reference sequences above followed by a calculation of R/S ratios
in DP receptors or EP2 receptors. As a similar logic of R/S ratio of
stochastic rate in evolution, the R/S ratio of stochastic frequencies
of DP receptors was 16/4 = 4.00 > 1, whereas that of EP2 receptors
was 4/8 = 0.50 < 1; therefore, the R/S ratio of frequencies was 8-fold
less in EP2 receptors than in DP receptors. The R/S ratio of DP
receptors was the highest among the other prostanoid receptors
examined, whereas that of EP2 receptors was the 2nd lowest after
TPa receptors (Supplemental Table I). Therefore, EP2 receptors
exhibited more constraints to the replacement of amino acids than
DP receptors.Similar results were observed when mouse DP and EP2 recep-
tors were compared. The numbers of mutations on the CDS of
mouse DP and EP2 receptors were extracted from the database of
the sequences of 17 key mouse strains from the Mouse Genome
Project [28]. As shown in Fig. 3 and 19 nucleotide changes and 9
amino acid substitutions were detected in mouse DP receptors
(R/S ratio = 0.90, Supplemental Table I). As shown in Fig. 4, 8
nucleotide changes and 2 amino acid replacement were observed
in mouse EP2 receptors (R/S ratio = 0.33, Supplemental Table I).
Although these results were extracted from limited genome
sequences, mouse EP2 receptors also appeared to exhibit more
constraints than mouse DP receptors.
Fig. 2. Mutations in the coding sequences of human EP2 receptors extracted from the 1000 genome project database. The chromosome, nucleotide, and amino acid positions
of human EP2 receptors were referred from GRCh37.p13 of NM_000956.3 (nucleotide ID) and NP_000947.2 (protein ID). The red ﬁlled frames were missense, non-sense, or
frame shifted variants (amino acid position: contig reference amino acid/changed amino acid). The light orange ﬁlled frames were synonymous variants (amino acid position:
silent mutation ‘‘sm’’).
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Genetic variants concerning the asthma susceptibility have
been identiﬁed and evaluated in both DP and EP2 receptors, espe-
cially in promoter, intron, and/or untranslated region(s), [7,33–37].
These variants do not change the amino acid sequences of the
receptors, but may alter the levels and/or timing of protein expres-
sion [33]. However, the most effective polymorphisms may be
alternations in genes encoding protein sequences, which could
alter protein function(s). With respect to mutations in the CDS
regions of DP and EP2 receptors regarding susceptibility to asthma,
several alleles have been identiﬁed in DP receptors; rs187903098,
rs41312502, and rs17125273 (Supplemental Table II); however,
they had no signiﬁcant effects and/or were not studied in more
detail because their frequencies were less than 1% [34,36]. To the
best of our knowledge, no allele change has been reported within
the CDS regions of EP2 receptors relating to asthma and other
diseases [20,35]. Therefore, previous ﬁndings were consistent with
the results of the present study; the CDS of EP2 receptors may
exhibit more constraints to changes than that of DP receptors.
As described earlier, the duplication of genes is of importance
in eukaryotes for the acquisition of genetic novelty and newfunctions. Thus, duplicated genes are likely to be required inequal-
ity; either one copy of the gene becomes non-functional, acquiring
novel and/or beneﬁcial functions, or both copies retain the partially
compromised and provide the overall function that have provided
by the single ancestral gene [29–32]. Given the attention to the dis-
tribution of each duplicated gene pairs, EP2 receptors are widely
distributed in tissues and have important functions, whereas DP
receptors are the least abundant and are not as extensively distribut-
ed [4]. A previous study suggested that PGE2-sensitive receptors
were the ancestral receptor [38]; therefore, based on the numbers
of mutations detected in the receptors examined in this study, we
speculated that DP receptors have acquired and/or have been
acquiring novel functions as the duplicated copy of EP2 receptors.
A few fundamental questions have arisen in respect to the
results obtained in the present study. It remains unclear why EP2
receptors, but not DP receptors are genetically constrained. Studies
using EP2 receptor knockout mice may provide possible insight for
this question. Thus, EP2 receptor knockout mice were previously
reported to exhibit marked defects in ovulation and fertilization
in vivo; impaired ovulation and signiﬁcant reductions in fertiliza-
tion that reduced embryo implantation were observed in female
mice [39,40]. Impaired synaptic plasticity and cognitive functions
Fig. 3. Mutations in the coding sequences of mouse DP receptors extracted from the mouse genome project database. The chromosome, nucleotide, and amino acid positions
of human DP receptors were referred from GRCm38.p2 of NM_008962.4 (nucleotide ID) and NP_032988.3 (protein ID). The red ﬁlled frames were missense, non-sense, or
frame shifted variants (amino acid position: contig reference amino acid/changed amino acid). The light orange ﬁlled frames were synonymous variants (amino acid position:
silent mutation ‘‘sm’’). The variants that had no rs ID were newly extracted from the mouse genome project database.
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hippocampus were also detected in EP2 receptor knockout mice
[41]. Moreover, mice lacking EP2 receptors were more severely
affected by ischemic associated damage with strokes [41]. These
ﬁndings indicated that neuronal EP2 receptors appear to have the
ability to promote neuronal plasticity and neuroprotection. There-
fore, defects in EP2 receptors may not be transmitted to offspring,
due to infertility and/or neuronal issues; therefore, the EP2 recep-
tor is plausibly very important for preserving not only individuals,
but also species. However, these knockout mice were not com-
pletely infertility; the ova of these mice could be fertilized in vitro
[39,40]. Thus, another unknown factor(s) and/or cause(s) mayexist, e.g. the effects of receptor loss on the reproductive capability
of EP2 receptor knockout male mice that would limit the passage
of the gene to their offspring, and needs to be elucidated in future
studies.
Since PGD2 almost exclusively regulates one of the most impor-
tant vital activities, sleep, it still remains unclear why DP receptors
do not exhibit the same constraints as EP2 receptors. A previous
study demonstrated that baseline sleep–wake patterns were not
altered in DP receptor knockout mice, indicating that the DP recep-
tor-mediated sleep systemmay not be crucial for basal sleep–wake
regulation [13]. The existence of an alternative compensated
system for DP receptor knockout has been suggested to explain
Fig. 4. Mutations in the coding sequences of mouse EP2 receptors extracted from the mouse genome project database. The chromosome, nucleotide, and amino acid positions
of human EP2 receptors were referred from GRCm38.p2 of NM_008964.4 (nucleotide ID) and NP_032990.1 (protein ID). The red ﬁlled frames were missense, non-sense, or
frame shifted variants (amino acid position: contig reference amino acid/changed amino acid). The light orange ﬁlled frames were synonymous variants (amino acid position:
silent mutation ‘‘sm’’). The variants that had no rs ID were newly extracted from the mouse genome project database.
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abundantly expressed and not widely distributed in body [4], a
compensatory system may exists in a local area, that could help
these receptors become less constrained than the widely distribut-
ed EP2 receptors [4]. Hence, DP receptors may have an important
part in, but are not necessarily essential for the basal sleep–wake
regulation.
It has yet to be conﬁrmed whether data from 1092 people were
sufﬁcient to support our conclusions. However, all the mutations in
DP and EP2 receptors that we extracted from the database were
already posted on the NCBI dbSNP website (www.ncbi.nlm.
nih.gov/SNP/); 106 SNPs were posted for human DP receptors, con-
sisting of 82 amino acid substitutions and 24 silent mutations (R/S
ratio is 82/24 = 3.42), and 51 SNPs were posted for human EP2
receptors, comprising 27 amino acid substitutions and 24 silent
mutations (R/S ratio is 27/24 = 1.13) (Supplemental Table II). The
numbers used here for the ratio calculation were extracted from
the assembled data posted on NCBI database, which are incom-
mensurable between each receptors; therefore, the R/S ratios from
the dbSNP site could not be fully comparable to each receptors as
well as to the results of the present study. Notwithstanding, the
ratios calculated using the dbSNP website led to similar tendencies,
which did not contradict our conclusions. Although data from 1092
people may not have been sufﬁcient, we believe our conclusions to
be mostly reliable in this present point.5. Conclusions
It is plausible to say that the ﬁndings shown in this manuscript
were simply attributed to the stability of CDS, i.e. EP2 receptors
would be more stable in CDS than that in DP receptors. Alternative-
ly, we speculated that EP2 receptors may have been preserved for
very speciﬁc and/or irreplaceable functions, at least in mice and
humans. Deﬁnitely, we need to validate the stability of CDS and
whether each mutation can alter the original functions, e.g. by
using the HEK293 cells expressing mutated DP and/or EP2 recep-
tors in the future. However, given an overviewed discussion above,
DP receptors may be still in the rapid evolutional stage. The
involvement of DP receptors in redundant and/or extreme reac-
tions by the immune-system, such as allergies, atopy, and asthma,
may be the result of an ongoing process to gain new functions.
Thus, DP receptors may acquire another novel function in the
future that may not be possible if they exhibit the same constraints
as their original counter part fellows, the EP2 receptors.Acknowledgments
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